Stonehage Fleming Financial Services Holdings Ltd Makes New Investment in West Pharmaceutical Services, Inc. $WST

Stonehage Fleming Financial Services Holdings Ltd bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 340,263 shares of the medical instruments supplier’s stock, valued at approximately $122,154,000. West Pharmaceutical Services accounts for approximately 4.2% of Stonehage Fleming Financial Services Holdings Ltd’s holdings, making the stock its 13th biggest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of Nova Scotia raised its stake in West Pharmaceutical Services by 337.8% during the 1st quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after purchasing an additional 50,402 shares during the period. Hsbc Holdings PLC boosted its position in shares of West Pharmaceutical Services by 23.3% in the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after buying an additional 27,745 shares during the period. Renaissance Technologies LLC boosted its position in shares of West Pharmaceutical Services by 100.2% in the first quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after buying an additional 104,924 shares during the period. Conestoga Capital Advisors LLC grew its holdings in shares of West Pharmaceutical Services by 6.7% during the first quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after buying an additional 8,179 shares in the last quarter. Finally, Ilmarinen Mutual Pension Insurance Co purchased a new position in shares of West Pharmaceutical Services during the fourth quarter valued at $3,027,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on WST. Wolfe Research initiated coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Citigroup lifted their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Stock Performance

WST stock opened at $346.67 on Friday. The firm has a 50 day moving average of $350.35 and a two-hundred day moving average of $303.37. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a market capitalization of $24.40 billion, a price-to-earnings ratio of 44.39, a P/E/G ratio of 2.45 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same quarter last year, the firm earned $1.84 EPS. West Pharmaceutical Services’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.